Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Yap, TA
90  Ergebnisse:
Personensuche X
?
1

A HUWE1 defect causes PARP inhibitor resistance by modulati..:

Pettitt, SJ ; Shao, N ; Zatreanu, D...
doi:10.1038/s41388-023-02782-8.  , 2023
Link: https://doi.org/10.1038/..
 
?
2

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Co..:

Yap, TA ; Krebs, MG ; Postel-Vinay, S...
1078-0432.CCR-21-1032.  , 2023
Link: https://repository.icr.a..
 
?
3

Radiological evaluation of malignant pleural mesothelioma -..:

Collins, DC ; Sundar, R ; Constantinidou, A...
BMC cancer, 2020, 20 (1), pp. 1210 - ?.  , 2021
Link: https://repository.icr.a..
 
?
4

Radiological evaluation of malignant pleural mesothelioma -..:

Collins, DC ; Sundar, R ; Constantinidou, A...
BMC Cancer.  , 2021
Link: http://hdl.handle.net/10..
 
?
5

SARS-CoV-2 vaccination and phase 1 cancer clinical trials:

Yap, TA ; Siu, LL ; Calvo, E...
Yap , TA , Siu , LL , Calvo , E , Lolkema , M , Lorusso , PM , Soria , JC , Plummer , R , de Bono , JS , Tabernero , J & Banerji , U 2021 , ' SARS-CoV-2 vaccination and phase 1 cancer clinical trials ' , The Lancet Oncology , vol. 22 , no. 3 , pp. 298-301 . https://doi.org/10.1016/S1470-2045(21)00017-6.  , 2021
Link: https://pure.eur.nl/en/p..
 
?
6

The National Lung Matrix Trial of personalized therapy in l..:

Middleton, G ; Fletcher, P ; Popat, S...
https://discovery.ucl.ac.uk/id/eprint/10112471/1/NLMT%20Nature%20Accepted.pdf.  , 2020
Link: https://discovery.ucl.ac..
 
?
7

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibi..:

Rafii, S ; Roda, D ; Geuna, E...
Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, 21 (8), pp. 1869 - 1876.  , 2020
Link: https://repository.icr.a..
 
?
8

Clinical brca1/2 reversion analysis identifies hotspot muta..:

Pettitt, SJ ; Frankum, JR ; Punta, M...
https://discovery.ucl.ac.uk/id/eprint/10175689/1/EMS128591.pdf.  , 2020
Link: https://discovery.ucl.ac..
 
?
9

Triplet Therapy with Palbociclib, Taselisib, and Fulvestran..:

Pascual, J ; Lim, JSJ ; Macpherson, IR...
Cancer discovery, 2020.  , 2020
Link: https://repository.icr.a..
 
?
10

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970..:

Yap, TA ; O'Carrigan, B ; Penney, MS...
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 38 (27), pp. 3195 - 3204.  , 2020
Link: https://repository.icr.a..
 
?
11

Radiological evaluation of malignant pleural mesothelioma -..:

Collins, DC ; Sundar, R ; Constantidinou, A...
BMC Cancer.  , 2020
Link: http://hdl.handle.net/10..
 
?
12

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibi..:

Yap, TA ; Kristeleit, R ; Michalarea, V...
Cancer discovery, 2020, 10 (10), pp. 1528 - 1543.  , 2020
Link: https://repository.icr.a..
 
?
13

A phase I study to assess afatinib in combination with carb..:

O'Brien, MER ; Sarker, D ; Bhosle, J...
Cancer chemotherapy and pharmacology, 2018, 82 (5), pp. 757 - 766.  , 2019
Link: https://repository.icr.a..
 
?
14

High frequency of radiological differential responses with ..:

Perez-Lopez, R ; Roda, D ; Jimenez, B...
Oncotarget, 2017, 8 (61), pp. 104430 - 104443.  , 2018
Link: https://repository.icr.a..
 
?
15

Metabolic biomarkers of response to the AKT inhibitor MK-22..:

Al-Saffar, NMS ; Troy, H ; Wong Te Fong, A-C...
British journal of cancer, 2018, 119 (9), pp. 1118 - 1128.  , 2018
Link: https://repository.icr.a..
 
1-15